Plné znění - 47/2014 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod - Mezinárodní standard) Mezinárodní úmluvy proti dopingu ve sportu

47/2014 Sb. m. s.

Sdělení

INFORMACE

47

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,

xxxxxx xx xxxx x xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx věcí x. 58/2007 Sb. m. x. x x. 46/2008 Sb. x. x. x xxxxxxxxx xxxxxxx Ministerstva zahraničních xxxx x. 98/2013 Xx. x. x. x Xxxxxxxxxxx úmluvě xxxxx dopingu xx xxxxxx

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 11. listopadu 2013 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxxx xxxxxxxxxx látek x xxxxx - Mezinárodní xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx dopingu ve xxxxxx.¹⁾

X xxxxx xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Parlament České xxxxxxxxx a xxxxxxxxx xxxxxxxxx xxxxxxxx listinu x xxxxxxx změny Xxxxxxx X Českou xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx X xxxxxxxxx x xxxxxxxx v xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. ledna 2014 x tímto xxxx xxxxxxxxx v xxxxxxxx x pro Xxxxxx xxxxxxxxx. Dnem xxxxxx xxxxxx xxxxx Xxxxxxx I v xxxxxxxx přestalo xxxxxx xxxxx Přílohy X Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx ve xxxxxx xxxxxx od 1. xxxxx 2013 x xxxxxxxxx pod č. 98/2013 Sb. m. s.

Xxxxxxxx xxxxx Přílohy X x xxxx překlad xx xxxxxxx xxxxxx xx vyhlašují xxxxxxxx.

¹⁾ Xxxxxxxxxxx úmluva xxxxx xxxxxxx xx sportu xxxxxxx dne 19. xxxxx 2005 x Xxxxxx xxxx xxxxxxxxx xxx č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

XXXXXXXXXXX XXXXXX PROTI XXXXXXX XX XXXXXX
Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx
Xxxxx, 1. xxxxx 2014

XXXXXX XXXXXXXXXX XXXXX X METOD DOPINGU XXX ROK 2014

SVĚTOVÝ XXXXXXXXXXXXX XXXXX

Xxxxxx xx 1. ledna 2014

Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx kodexu xxxxxxx Xxxxxxxx xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx látek xx xxxxxx S1, X2, S4.4, S4.5 x X6(x) x Xxxxxxxxxx xxxxx M1, X2 x M3.

LÁTKY X XXXXXX XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

XXXXXXXX LÁTKY

S0. XXXXXXXXXXX XXXXX

Xxxxxxxxx farmaceutická xxxxx, která xxxx xxxxxxxx x následujících xxxxxxx Seznamu x xxxx xxxxxxxx xxxxxxxxx xxx humánní xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx regulačním xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx nebo xxxxxxxxx xxxxxx xxxxxxx xxxx xx xxxxxxxx registraci, xxxxxxxxxx drogy, xxxxx xxxxxxxxx xxxxx pro xxxxxxxxxxx použití), xx xxxxxxxx xxxxx.

X1. XXXXXXXXXX XXXXX

Xxxxxxxxxx látky xxxx xxxxxxxx.

1. ANDROGENNÍ ANABOLICKÉ XXXXXXXX (XXX):

(x) Exogenní* XXX, zahrnující:

1-androstendiol (5α-androst-1-en-3b,17β-diol); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); bolandiol (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx ([1,2]xxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx); dehydrochlormethyltestosteron (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-methyl-5α-androst-2-en-17β-ol); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-xxxxxx-4-xx-17α-xx); fluoxymesteron; xxxxxxxxxx; xxxxxxxxx (17α-methyl[1,2,5]oxadiazolo[3',4':2,3]-5α-androstan-17β-ol); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-dihydroxyandrost-4-en-3-on); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; metandienon (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx); xxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9-dien-3-on); xxxxxx-1-xxxxxxxxxxx (17β-hydroxy-17α-methyl-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; metribolon (xxxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9,11-trien-3-on); miboleron; xxxxxxxxx; 19-norandrostendion (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; norethandrolon; xxxxxxxxxxxx; xxxxxxxx; oxandrolon; oxymesteron; xxxxxxxxxx; xxxxxxxxxxx (17β-[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4,:2,3]-5α-androstane); xxxxxxxxx; xxxxxxxxxx; stenbolon; 1-xxxxxxxxxxx (17β-hydroxy-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx (17β-xxxxxxxxxx-4,9,11-xxxxx-3-xx) x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxx** XXX, xxxxx jsou xxxxxx exogenně:

Androstendiol (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (androst-4-en-3,17-dion), dihydrotestosteron, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX), 3β-xxxxxxxxxxxxx-5-xx-17-xx), xxxxxxxxxxx a xxxxxx xxxxxxxxxx x xxxxxxx, xxx ne x omezením pouze xx xx:

5α-xxxxxxxxx-3α,17α-xxxx	5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)
5α-xxxxxxxxx-3α,17β-xxxx	xxx-xxxxxxxxxxxxxxxxxx
5α-xxxxxxxxx-3β,17α-xxxx	xxxxxxxxxxxxxx
5α-xxxxxxxxx-3β,17β-xxxx	xxxxxxxxxxxxxx
xxxxxxx-4-xx-3α,17α-xxxx	3α-xxxxxxx-5αxxxxxxxxx-17-xx
xxxxxxx-4-xx-3α,17β-xxxx	3β-xxxxxxx-5αxxxxxxxxx-17-xx
xxxxxxx-5-xx-3β,17α-xxxx	7α-xxxxxxx-XXXX
xxxxxxx-5-xx-3α,17α-xxxx	7β-xxxxxxx-XXXX
xxxxxxx-5-xx-3α,17β-xxxX	7-xxxx-XXXX
xxxxxxx-5-xx-3β,17α-xxxx	19-xxxxxxxxxxxxxx
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx)	19-xxxxxxxxxxxxxxxxx

Xxx účely skupiny xxxx xxxxx:

* "xxxxxxxx" xx xxxxxxxx x xxxxx, kterou xxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxx.

** "xxxxxxxxx " xx xxxxxxxx k látce, xxxxxx xxxx normálně xxxxxxxxx xxxxxxxxx.

2. Ostatní xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx, xxxxxxxxxx modulátory androgenových xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, xxxxxxxxxx, xxx xx s omezením xxxxx xx xx.

X2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX A XXXXXXXX XXXXX

Xxxxxxxxxxx látky x xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx xxxx zakázány:

1. Xxxxx stimulující xxxxxxxxxxx (xxxx. erytropoetin (EPO), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX), xxxxxxxxxxx /Xxxxxxxx/);

2. Xxxxxxxxxxxxxxxxxx (XX) a Xxxxxxxxxxxx xxxxxx (LH) x jejich xxxxxxxxxx xxxxxxx x xxxx;

3. Xxxxxxxxxxxxxx x jejich xxxxxxxxxx xxxxxxx;

4. Růstový xxxxxx (GH) a xxxx xxxxxxxxxx xxxxxxx x xxxxxxxx xxxxxxx xxxxxxx xxxxxx-1 (XXX-1).

Xxxxx xxxx jsou xxxxxxxx xxxxxxxxxxx xxxxxxx faktory:

Fibroblastové xxxxxxx xxxxxxx (XXXx), xxxxxxxxxxxx xxxxxxx faktor (XXX), xxxxxxxxxx xxxxxxx xxxxxxx (XXX), růstový xxxxxx xxxxxxxx z xxxxxxxx destiček (XXXX) x vaskulárně-endoteliární xxxxxxx xxxxxx (XXXX), stejně xxxx xxxxxxxxx jiné xxxxxxx xxxxxxx ovlivňující xxxxxxx xxxx xxxxxxxxx xxxxxxxx svalů, šlach x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx typy xxxxxxxxx xxxxxx;

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx účinky.

S3. BETA2- XXXXXXXX

Xxxxxxx xxxx-2 xxxxxxxx, xxxxxx xxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (např. x- x l-), xxxx xxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxxxxxxx 1600 xxxxxxxxxx xx 24 hodin), inhlalačního xxxxxxxxxxx (xxxxxxxxx xxxxxx xxxxx 54 xxxxxxxxxx xx 24 xxxxx) x salmeterolu, pokud xxxx xxxxxx x xxxxxxxx v xxxxxxx x doporučeným xxxxxxxx xxxxxxx xxxxxxx.

Xxxxxxxxxx xxxxxxxxxxx x moči x xxxxxxxxxxx vyšší xxx 1000 ng/ml x xxxxxxxxxx xxxxxxxxxxx v xxxx x xxxxxxxxxxx xxxxx než 40 xx/xx nebude xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxx xxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx nález, xxxxx xxxxxxxxx xxxxxxxxx kontrolovanou xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxxxxx terapeutické xxxxxxxxx xxxxx nižší xxx xxxx xxxxxxx xxxxxxx.

X4. XXXXXXXXX X XXXXXXXXXXX MODULÁTORY

Zakázané xx xxxxxxxxxxx:

1. Xxxxxxxxxx aromatáz, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx), xxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx ne x xxxxxxxx xxxxx xx xx.

2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), zahrnující:

Raloxifen, xxxxxxxxx, xxxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.

3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:

Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxx xx x omezením xxxxx na xx.

4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx včetně xxxxxxxxxx xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.

5. Metabolické xxxxxxxxxx:

x) Xxxxxxxx;

x) Xxxxxxxx xxxxx aktivovaný peroxizomovými xxxxxxxxxxxxx /Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxxx δ (XXXXδ) xxxxxxxx/ (xxxx. XX 1516) a Xxxxxxxx proteinkinasové xxx xxxxxxxxxx AMP v xxxxxxxxxxx x XXXX xxxxx /PPARδ-AMP-activated xxxxxxx xxxxxx (AMPK) xxxx xxxxxxxx/ (např. XXXXX)

X5. XXXXXXXXX A OSTATNÍ XXXXXXXXX XXXXX

Xxxxxxxxx látky xxxx xxxxxxxx. Xxxxxxxx:

Xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x mannitolu), xxxxxxxxxx x xxxxx xxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxx xxxx xxxxxxxx.

Xxxxxxxxx xxxxxxxx:

Xxxxxxxxxxxx, amilorid, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxx etakrynová, xxxxxxxxx, spironolakton, thiazidy (xxxx. bendroflumethiazid, hydrochlorothiazid, xxxxxxxxxxxxx), xxxxxxxxxx, vaptany (xxxx. xxxxxxxxx) a xxxxx xxxxx s xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx drospirenonu, xxxxxxxxx x xxxxxxxxx xxxxxx dorzolamidu x xxxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx).

Xxx xxxxxxx (Xxx Xxxxxxx, xxxxxxxx Xxxx Xxxxxx) jakéhokoliv xxxxxxxx xxxxx xx stanoveným xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, salbutamol, xxxxx, xxxxxxx, xxxxxxxxxxxx a xxxxxxxxxxxxx) xx xxxxxxx x diuretikem xxxx xxxxx maskovací xxxxxx xx vyžadováno udělení xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx xx tuto látku xxxxx x xx, xxxxx xxx xxxx xxxxxxx xx diuretikum xxxx jinou xxxxxxxxx xxxxx.

XXXXXXXX METODY

M1. XXXXXXXXXX X XXXX X XXXXXXXX KOMPONENTAMI

Zakázané xx xxxxxxxxxxx:

1. Xxxxxx nebo xxxxxxxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, xxxxxxxx (xxxxxxxxx) xxxx heterologní xxxx xxxx červených krvinek x jim xxxxxxxxx xxxxxxxx xxxxxxxxxxx původu xx xxxxxxxxx systému.

2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx, zahrnující xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx. xxxxxx xxxxxxxx založené xx xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), xxx xx x omezením xxxxx xx xx. Xxxxxxxxxxxx kyslíkem xxxxxxxx xxxx.

3. Xxxxxxxxx forma xxxxxxxxxxxxxxx manipulace x xxxx xxxx s xxxxxxxx xxxxxxxxxxxx fyzikálními xxxx xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxxxxx, xxxx pokus x xxxxxx, xx xxxxxx xxxxxxx integritu x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Dopingové xxxxxxxx. Xx zahrnuje xxxxxx x/xxxx xxxxxx (xxxx. xxxxxxxxxx) moči, xxx xx x xxxxxxxx xxxxx xx xx.

2. Nitrožilní infuze x/xxxx xxxxxxx xxxx xxx 50 xx xx 6 xxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx metod.

M3. XXXXXX DOPING

Z důvodu xxxxxxxxxx ke xxxxxxx xxxxxxxxxxx xxxxxx je xxxxxxxx následující:

1. Xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxx;

2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx modifikovaných xxxxx.

XXXXX X XXXXXX XXXXXXXX XXX XXXXXXX

Xxxxx xxxxxxxxx X0 xx X5 x M1 xx X3 uvedených xxxx xxxx Xxx Xxxxxxx xxxxxxxx i xxxxxxxxxxx xxxxxxx:

XXXXXXXX LÁTKY

S6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx včetně xxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. x- x x-) xxxx xxxxxxxx, x výjimkou xxxxxxxx xxxxxxxxx v xxxxxxx jejich xxxxxxxx xxxxxxx a stimulancií xxxxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2014*.

Xxxxxxxxxxx xxxxxxxx:

(x) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx, xxxxxxxxxx, amfetamin, xxxxxxxxxxx, amifenazol, xxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, fenkamin, xxxxxxxxxxx, fenproporex, fentermin, xxxxxxxxxxxx /4-xxxxxxxxxxxxxx (karfedon)/, xxxxxxxxxx, klobenzorex, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx (x-), xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx.

Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxx x tomto xxxxxxxx, je Specifickou xxxxxx.

(x) Xxxxxxxxxx stimulancia (xxxxxxxx):

Xxxxxxxxx (epinefrin)****, xxxxxxxxxxx, xxxxxxxxxxxxxxxxx, efedrin***, xxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, fenprometamin, xxxxxxxxxx, hydroxyamfetamin (parahydroamfetamin), xxxxxxxxxxxx, xxxxx**, xxxxxxx x xxxx analoga (xxxx. xxxxxxxx, xxxxxxxxx, xxxx-xxxxxxxxxxxxxxxxxxxxx), xxxxxxxxxxxxxxx, meklofenoxát, xxxxxxxxxxxx***, xxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxx (dimetylpentylamin), xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, oxilofrin (xxxxxxxxxxxxx), xxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx), xxxxxxxxxxxx, xxxxxxxxxxxxx x další xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

* Xxxxxxxxxxx xxxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2014 (xxxxxxxxx, fenylefrin, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxx) nejsou xxxxxxxxxx xx Xxxxxxxx látky.

** Xxxxx xx xxxxxxxx xxxxx xxx koncentraci xxxxx xxx 5 xxxxxxxxxx x 1 xx xxxx.

*** Efedrin x xxxxxxxxxxxxx xxxx xxxxxxxx při xxxxxxxxxxx xxxxx než 10 xxxxxxxxxx x 1 xx xxxx.

**** Lokální xxxxxx xxxxxxxxxx (xxxxxxxxxx) (xxxx. xxxxx, oční xxxxxxxx) xxxx xxxx xxxxxx xxxxxxxx x xxxxxxxxx anestetiky není xxxxxxxx.

***** Xxxxxxxxxxxxx xx xxxxxxx, xxxxx xxxx xxxxxxxxxxx v xxxx xx vyšší xxx 150 xxxxxxxxxx na xxxxxxxx.

X7. NARKOTIKA

Zakázané xx xxxxxxxxxxx:

Xxxxxxxxxxx, dextromoramid, xxxxxxxxx(xxxxxx), xxxxxxxx a jeho xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, oxykodon, xxxxxxxxx, xxxxxxxxxx, xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxx (xxxx. hašiš, xxxxxx x xxxxxxxxx) xxxx xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) x xxxxxxxxxxxxxx (např. "Xxxxx", XXX018, JWH073 x XX-210) xxxx xxxxxxxx.

X9. XXXXXXXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx nebo xxxxxxxxxxxxx xxxxxxxx xxxx zakázané.

LÁTKY XXXXXXXX X XXXXXXXX XXXXXXXX

X1. ALKOHOL

Alkohol (etanol) xx xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx sportech. Detekce xx xxxx xxxxxxxx xxxxxxxx zkouškou a/nebo xxxxxxxx krve. Xxxxxxx xxxxxxx xxx xxxxxxxx xxxxxxxxxxx pravidla xx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxxx x krvi 0.10 x/x.

• Automobilový xxxxx (XXX)

• Karate (XXX)

• Xxxxxxx xxxxxx a xxxxxxxxxxxx (FAI)

• Xxxxxxxxxxx (XX)

• Xxxxxxxxxxx xxxxx (XXX)

• Xxxxx motorismus (XXX)

X2. XXXX-XXXXXXXXX

Xxxxx xxxx xxxxx xxxxxx, beta-blokátory xxxx xxxxxxxx xxxxx Xxx Soutěži x xxxxxxxxxxxxx xxxxxxxx.

• Xxxxxxxxxxxx xxxxx (FIA)

• Xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)

• Xxxx (IGF)

• Xxxxxxxxxxx (XX) (xxxxxxxx také Xxxx xxxxxx)

• Xxxxxxxx (XXX) - skoky xx xxxxxx a xxxxxxxxxxx lyžování-skoky x X-xxxxx, a xxxxxxxxx X-xxxxx x "xxx xxx"

• Xxxxxxx (XXXX, XXX) (xxxxxxxx také Xxxx soutěž)

• Xxxxx (XXX)

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, labetalol, xxxxxxxxxxx, xxxxxxxxxxxx, metoprolol, xxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, timolol, ale xx s xxxxxxxx xxxxx xx ně.

Informace

Právní předpis x. 47/2014 Xx. x. x. nabyl xxxxxxxxx xxxx 20.9.2014.

Xxxxxx xxxxxxx x. 47/2014 Xx. x. s. byl xxxxxx xxxxxxx xxxxxxxxx č. 19/2017 Sb. m. s. x účinností xx 6.4.2017.

Xxxxx jednotlivých xxxxxxxx norem jiných xxxxxxxx xxxxxxxx x xxxxxxxx xxxx aktualizováno, xxxxx xx xxxx xxxxxx derogační xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.